echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Cipla obtains final approval for the generic version of GlaxoSmithKline

    Cipla obtains final approval for the generic version of GlaxoSmithKline

    • Last Update: 2021-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Cipla Limited today announced that its 20 mg sumatriptan nasal spray abbreviated new drug application (ANDA) has received final approval from the US Food and Drug Administration (US FDA)

    Cipla’s U.
    Pharmacopoeia 20 mg sumatriptan nasal spray is a generic version of the Class AB generic treatment of GlaxoSmithKline Imtrex® nasal spray


    Imitrex® nasal spray is a serotonin (5-HT1B/1D) receptor agonist (triptan), suitable for the acute treatment of adult migraine with or without aura


    According to data from IQVIA (IMS Health), the sales of Imitrex® 20mg nasal spray and its generic drugs in the United States for the 12-month period ending December 2020 are approximately US$53.
    3 million


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.